News of Note—Abzena invests in California, Catalent in China

Cancer in newspaper clipping

> Abzena is investing $20 million to add two manufacturing suites at the 500 liter and 2000 liter scale, at its manufacturing facility in San Diego, California. Release

> Catalent Pharma Solutions will invest $2.5 million in a second clinical supply facility in Shanghai, China, which will employ about 100 people when it opens in early 2019. Release

> The FDA is instituting new protocols to gather data from sterile injectable manufacturers in an effort to raise quality and avoid shortages. Release


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> Dave Tudor, Ph.D., previously head of manufacturing strategy for GlaxoSmithKline, has been appointed managing director of the Medicines Manufacturing Innovation Centre, a collaboration among GSK, AstraZeneca, CPI and the University of Strathclyde in Scotland. Release

> For the first time in 30 years the U.S. will have a domestic supply of Iodine-131 (I-131), a critical radioisotope for diagnosing and treating thyroid cancer and hyperthyroidism. The supply is being produced by the University of Missouri. Release

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

As flights from China contract and prices double, the logistics of getting products out of China is a major challenge. 

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.